The median progression-free survival was not reached with the combination therapy and was @ months with ipilimumab monotherapy ( hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death , @ ; @ % confidence interval , @ to @ ; P < @ ) .